Evidence map›Paper›PMID 33489451›Full record

ReviewAmerican journal of blood research2020

Therapy-related acute myeloid leukemia and its prevention.

Gennady Belitsky, Timur Fetisov, Kirill Kirsanov, Ekaterina Lesovaya, Olga Vlasova, Marianna Yakubovskaya

Open access · greenAbstract readReview
In one paragraph

Review in American journal of blood research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Gennady BelitskyDepartment of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.
Timur FetisovDepartment of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.
Kirill KirsanovDepartment of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.
Ekaterina LesovayaDepartment of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.
Olga VlasovaDepartment of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.
Marianna YakubovskayaDepartment of Chemical Carcinogenesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation Moscow 115478, Russia.
National Medical Research Center of Cardiology · RUPeoples' Friendship University of Russia · RURyazan State Medical University named after Academician I.P. Pavlov · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSecondary tumors, including therapy-related acute myeloid leukemia (t-AML), represent one of the most undesirable side effects of chemotherapy, which arise several years after primary cancer treatment. This review aims to analyze the current data on molecular pathogenesis of t-AML revealing potential criteria for predicting predisposition to the disease. Another objective is to analyze the information on promising approaches for t-AML prevention.

methodsWe analyzed studies regarding t-AML and possible approaches for cancer prevention of drug-induced tumors. Publications in the databases, such as SciVerse Scopus (948), PubMed (1837) and Web of Science (935) were used. Among 92 the most important publications cited in the review, 79 were published during the last decade.

resultsThe review provides the information concerning t-AML pathogenesis, molecular markers of primary cancer patients with high risk of t-AML. The role of the bone marrow niche in clonal hematopoiesis and t-AML pathogenesis is discussed. Current approaches for t-AML prevention both at the stage of therapy and at the latent period are described. Inhibition effects of polyphenols on cell proliferation and on the appearance of hemopoetic clones of indeterminate potential are proposed for t-AML prevention.

conclusionThe problem of the t-AML, a cancer induced by genotoxic chemotherapeutic drugs, is considered from the point of view of the fundamental mechanisms of chemical carcinogenesis, highlighting initiation and promotion stages. It enables to reveal the possible markers for the group of patients with high risk for t-AML and to demonstrate perspectives for the use of plant polyphenols for t-AML prevention.

Indexed as

cytotoxic drugsleukemiametastatic nichesplant polyphenolsprevention of secondary AMLstem cellsTherapy-related cancer

Identifiers

PMID33489451
PMCPMC7811901
OpenAlexW3123763418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.